| Name | Title | Contact Details |
|---|
Were developing tech to feed the world. The world is running out of phosphorus. Most of the worlds phosphorus is used to grow food to feed to animals to produce meat. Manure isnt returned to growing regions, and instead leads to algal blooms and nutrient pollution. Were fixing this problem with tech to produce fertilizer from manure, helping farmers grow better food at a price farmers can afford.
Figure is an AI Robotics company building the worlds first commercially viable autonomous humanoid robot. We are based in Sunnyvale, CA.
Kersia Group is a global leader in biosecurity and food safety, focused on ensuring the safety of food production, processing, distribution, and consumption. The company aims to create a food-safe world by providing innovative and sustainable solutions that prevent diseases and contamination throughout the food supply chain. Kersia offers a variety of services to enhance food safety and operational performance. These include plant sanitation assessments, inventory usage management, annual cleaning validation, routine plant visits, and sanitation audits. The company collaborates with clients to optimize sanitation programs, ensuring high hygiene standards and compliance with regulatory requirements. With a significant presence in the United States and headquartered in France, Kersia USA specifically addresses food safety challenges in the meat and poultry processing sectors. The company is dedicated to supporting various industries, including dairy and healthcare, by delivering tailored solutions that enhance operational efficiency.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.